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ABSTRACT 65 
Purpose: Tumor-derived cell-free DNA (cfDNA) from urine of patients with cancer offers 66 
non-invasive biologic material for detection of cancer-related molecular abnormalities 67 
such as mutations in Exon 2 of KRAS.  68 
Experimental Design: A quantitative, mutation-enrichment next-generation sequencing 69 
test for detecting KRASG12/G13 mutations in urine cfDNA was developed and results were 70 
compared to clinical testing of archival tumor tissue and plasma cfDNA from patients 71 
with advanced cancer.  72 
Results: With 90-110 mL of urine, the KRASG12/G13 cfDNA test had an analytical 73 
sensitivity of 0.002%-0.006% mutant copies in wild-type background. In 71 patients, the 74 
concordance between urine cfDNA and tumor was 73% (sensitivity, 63%; specificity, 75 
96%) for all patients and 89% (sensitivity, 80%; specificity, 100%) for patients with urine 76 
samples of 90-110 mL. Patients had significantly fewer KRASG12/G13 copies in urine 77 
cfDNA during systemic therapy than at baseline or disease progression (P=0.002). 78 
Compared with no changes or increases in urine cfDNA KRASG12/G13 copies during 79 
therapy, decreases in these measures were associated with longer median time to 80 
treatment failure (P=0.03). 81 
Conclusions: A quantitative, mutation-enrichment next-generation sequencing test for 82 
detecting KRASG12/G13 mutations in urine cfDNA had good concordance with testing of 83 
archival tumor tissue. Changes in mutated urine cfDNA were associated with time to 84 
treatment failure.  85 
 86 
  87 
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STATEMENT OF SIGNIFICANCE 88 
In patients with advanced cancers, mutation-enrichment next-generation sequencing 89 
detection of KRASG12/G13 mutations in urine cell-free DNA has good concordance with 90 
conventional clinical testing of archival tumor tissue, provided that the volume of 91 
collected urine is sufficient. Changes in mutated cell-free DNA correspond with time to 92 
treatment failure on systemic anticancer therapy. 93 
 94 
95 
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INTRODUCTION 96 
Detecting molecular alterations can provide guidance for personalized cancer therapy in 97 
patients with melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and 98 
other cancers (1-5). KRAS mutations are associated with poor prognosis in diverse 99 
cancer types and with lack of benefit from anti–epidermal growth factor receptor (EGFR) 100 
targeted monoclonal antibodies in colorectal cancer (3, 6-8). Currently, oncogenic 101 
alterations such as KRAS mutations are assessed in archival tumor tissue, but the tissue 102 
availability is often a limiting factor that precludes molecular analysis (9, 10). In addition, 103 
mutation assessment of primary tumor tissue or an isolated metastasis does not 104 
necessarily reflect the genetic make-up of metastatic disease owing to tumor 105 
heterogeneity (11-13). Different oncogenic mutations occur in different areas of a 106 
primary tumor, and the mutation statuses of the primary tumor and distant metastases 107 
are discrepant in approximately 20–30% of cases (12, 14). In addition, translational 108 
studies in EGFR-mutated NSCLC suggest that cancer genotype can change over time; 109 
for example, Sequist et al. demonstrated in a group of 37 patients with EGFR-mutant 110 
NSCLC who had pre-treatment and post-progression tumor biopsies that some 111 
mutations can occur and disappear over time (15). Tumor cells undergoing apoptosis or 112 
necrosis release small fragments of cell-free (cf) DNA, which can be identified in blood, 113 
urine, and other biologic materials and offers an alternative source of material for 114 
genomic testing (16). Unlike performing tissue biopsies, obtaining samples of urine or 115 
plasma cfDNA is less invasive, with less risk to patients at a lower cost, and can be 116 
repeated at different times and provide valuable information about genetic changes that 117 
occur during the disease evolution. In colorectal cancer, sensitive techniques such as 118 
BEAMing (beads, emulsion, amplification, magnetics) polymerase chain reaction (PCR), 119 
droplet digital PCR, and next-generation sequencing (NGS) detected low-frequency 120 
clones with KRAS mutations in plasma cell-free DNA (cfDNA) not detected by standard 121 
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clinical molecular testing, and these clones ultimately led to resistance to EGFR 122 
antibodies (17-20).  123 
Preliminary data suggest that molecular testing of urine cfDNA is feasible in 124 
patients with advanced cancers (10, 21, 22). The purpose of this study was to develop 125 
and validate molecular detection and quantification of exon 2 KRAS mutations 126 
(KRASG12/G13) in urine and plasma cfDNA specimens from patients with advanced 127 
cancers and determine whether this approach has acceptable concordance, sensitivity, 128 
and specificity with conventional clinical testing of archival tumor samples. In addition, 129 
this study sought to determine whether changes in KRASG12/G13 copy numbers in urine or 130 
plasma cfDNA are correlated with treatment outcomes.  131 
 132 
 133 
 134 
 135 
 136 
 137 
 138 
 139 
 140 
 141 
 142 
 143 
 144 
 145 
 146 
 147 
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METHODS 148 
Patients 149 
Patients with progressing advanced cancers and known KRAS mutation statuses 150 
from conventional clinical testing of their archival formalin-fixed, paraffin-embedded 151 
(FFPE) tumor tissue specimens (described in the Supplementary Methods) treated at 152 
The University of Texas MD Anderson, Niguarda Cancer Center, and the University of 153 
Southern California Norris Comprehensive Cancer Center were enrolled for urine and 154 
plasma collection from December 2012 to November 2015. Patients had the option of 155 
providing longitudinally collected samples during the course of their therapy. The study 156 
was conducted in accordance with the approval of the participating institutions’ 157 
Institutional Review Boards and/or with the guidelines of their Ethical Committees.  158 
 159 
Sample Collection and Processing 160 
Urine and plasma samples for cfDNA isolation were collected at the time of 161 
disease progression before treatment initiation and, if feasible, repeatedly during 162 
subsequent therapy. The recommended urine collection volume was 90–110 mL; 163 
however, amounts as small as 10 mL were also accepted. Urine samples were collected 164 
in 120-mL containers supplemented with preservative and stored at –70°C. For cfDNA 165 
extraction, urine was concentrated to 4 mL using Vivacell 100 concentrators (Sartorius 166 
Corp, Bohemia, NY) and incubated with 700 μL of Q-sepharose Fast Flow quaternary 167 
ammonium resin (GE Healthcare, Pittsburg, PA). Tubes were spun to collect sepharose 168 
and bound DNA. The pellet was resuspended in a buffer containing guanidinium 169 
hydrochloride and isopropanol, and the eluted DNA was collected as a flow-through 170 
using polypropylene chromatography columns (BioRad Laboratories, Irvine, CA). The 171 
DNA was further purified using QiaQuick columns (Qiagen, Germany).  172 
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At MD Anderson and Niguarda Cancer Center, whole blood was collected in 173 
ethylenediaminetetraacetic acid–containing tubes and centrifuged and spun twice within 174 
2 hours to yield plasma. At the University of Southern California, blood was collected in 175 
Cell-Free DNA BCT tubes (Streck, Omaha, NE), which allow storage for up to 2 weeks. 176 
The QIAamp Circulating Nucleic Acid kit (Qiagen, Valencia, CA) was used to isolate 177 
cfDNA from 1.5–4 mL of plasma according to the manufacturer’s instructions. 178 
 179 
KRAS Mutation Analysis in cfDNA 180 
We developed a new workflow to create an assay capable of detecting a low 181 
abundance of KRASG12/G13 mutations (≤ 0.01% in the wild-type [wt] DNA background) in 182 
short, highly fragmented urine cfDNA (Supplementary Fig. S1). The urine cfDNA 183 
extraction method was designed to preferentially isolate low-molecular-weight (< 400 bp) 184 
fragments of cfDNA. Quantitative analysis of 7 common mutations (G12A, G12C, G12D, 185 
G12R, G12S, G12V, and G13D) in codons 12 or 13 of exon 2 of the KRAS gene 186 
(KRASG12/G13 mutations) was performed using a mutation-enrichment PCR coupled with 187 
NGS (Trovagene, San Diego, CA). An ultra-short footprint PCR assay (gene-specific 188 
footprint 31 bp; overall amplicon length of 75 bp) was used to amplify highly degraded 189 
cfDNA KRASG12/G13 fragments. The PCR amplification utilized a preferential enrichment 190 
of KRASG12/G13-mutant cfDNA by using oligonucleotides complementary to wt KRAS 191 
DNA to block annealing of the PCR primers and to suppress the amplification of wt 192 
KRAS (Supplementary Fig. S2). PCR primers contained a 3' gene-specific sequence 193 
and a 5' common sequence that was used in the subsequent sample-barcoding step. 194 
The PCR enrichment cycling conditions utilized an initial 98°C denaturation step followed 195 
by an assay-specific 5 cycles of pre-amplification PCR and 30 cycles of mutation-196 
enrichment PCR. Custom DNA sequencing libraries were constructed and indexed using 197 
the Access Array System for Illumina Sequencing Systems (Fluidigm, San Francisco, 198 
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CA). The indexed libraries were pooled, diluted to equimolar amounts with buffer and the 199 
5% PhiX Control library, and sequenced on an Illumina MiSeq platform at a high depth 200 
(~200,000 reads) using 150-V3 sequencing kits (Illumina, San Diego, CA). Primary 201 
image analysis, secondary base calling, and data quality assessment were performed on 202 
the MiSeq instrument using RTAv1.18.54 and MiSeq Reporter v2.6.2.3 software. The 203 
analysis output (FASTQ files) from the runs was processed using custom sequencing 204 
reads counting and variant calling algorithms to tally the sums of total target gene reads 205 
(wt KRAS or mutant KRAS reads) that passed predetermined sequence quality criteria 206 
(qscore ≥ 20). A custom quantification algorithm was developed to accurately determine 207 
the absolute number of mutant DNA molecules in the source cfDNA sample. The 208 
algorithm quantifies the mutational copy number by incorporating into each sequencing 209 
run a corresponding reference sample set with known copy numbers for each of the 210 
seven most common KRASG12/G13 mutations.  Sequencing results from this reference 211 
sample set is used to generate standard curves and the mutant copy number from the 212 
source cfDNA sample is calculated by interpolation.  Results are standardized to a 213 
100,000 Genome Equivalents (GEq). 214 
The KRASG12/13 mutation detection was determined as the number of KRAS 215 
mutations detected above a pre-defined cutpoint which were specific for each of the 216 
seven KRAS mutations assessed. The pre-defined cutpoint for each KRAS mutation was 217 
calculated as the copy number obtained from the mean plus three standard deviations of 218 
non-specific signal (copy number) established by analyzing urine cfDNA samples from 219 
150 healthy volunteers and 24 patients with wt KRASG12/G13 metastatic cancer (by tumor 220 
tissue analysis). Similarly, assay cut-offs for plasma were established by analyzing 221 
plasma cfDNA samples from a separate cohort of 40 healthy volunteers and 80 patients 222 
with wt KRASG12/G13 metastatic cancer (by tumor tissue analysis). Detection cut-offs were 223 
standardized to 100,000 GEq. 224 
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 225 
Statistical Analysis 226 
Concordance between the mutation analyses of urine cfDNA, plasma cfDNA, and 227 
archival tumor specimens was calculated using a kappa coefficient. Overall survival (OS) 228 
was defined as the time from the date of study entry to the date of death or last follow-229 
up. Time to treatment failure (TTF) was defined as the time from the date of systemic 230 
therapy initiation to the date of removal from the treatment. The Kaplan-Meier method 231 
was used to estimate OS and TTF, and a log1 rank test was used to compare OS and 232 
TTF among patient subgroups. Cox proportional hazards regression models were fit to 233 
assess the association between patient characteristics and OS or TTF. The Spearman 234 
rank coefficient was used to assess correlations. All tests were 2-sided, and P values < 235 
0.05 were considered statistically significant. All statistical analyses were performed with 236 
the GraphPad (GraphPad Software, Inc., La Jolla, CA) or SPSS 23 (SPSS, Chicago, IL) 237 
software programs. 238 
 239 
 240 
 241 
 242 
 243 
 244 
 245 
 246 
 247 
 248 
 249 
 250 
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RESULTS 251 
Performance of the Assay in Detecting KRASG12/G13 Mutations in Urine cfDNA 252 
The performance of mutation-enrichment PCR coupled with NGS for the 253 
detection of KRASG12/G13 mutations in urine cfDNA was investigated by assessing fold 254 
mutation enrichment, lower limit of detection, and assay reproducibility in urine. Fold 255 
enrichment was assessed by spiking 5–500 copies of mutant DNA into 18,181 GEq of wt 256 
DNA (0.027%–2.7%). For the 7 most common KRASG12/G13 variants, 2,000- to 3,370-fold 257 
enrichment of mutant KRASG12/G13 fragments was obtained for an input of 5 copies of 258 
KRASG12/13 mutant DNA within 60 ng (18,181 GEq) of wt DNA (Fig. 1A and 1B). The 259 
resulting sequencing libraries comprised 69.5%–99.7% mutant reads, thus enabling 260 
sensitive mutation detection by NGS (Fig. 1A). Resulting fold-enrichment for 261 
KRASG12/G13-mutant fragments increased inversely with decreasing amount of mutant 262 
copies in the wt background (Fig.1B).  263 
When quantifying rare DNA fragments, the frequency distribution of the number 264 
of DNA molecules that will be present in each PCR tube upon repeated measurements 265 
can be predicted by the Poisson distribution. Herein, the lower limit of detection was 266 
defined as the lowest number of copies for which the frequency distribution of the copy 267 
number events upon repeated measurements fell within the 95% confidence interval (CI) 268 
of expected frequency distribution determined by Poisson statistics. For lower limit of 269 
detection verification, 20–80 repeated measurements were performed on a single 270 
multiplexed NGS run for a target spike-in level of 1 mutant KRASG12/G13 copy within 271 
18,181 GEq (60 ng) of wt KRAS DNA or for a target spike-in level of 2 mutant 272 
KRASG12/G13 copies within 100,000 GEq (330 ng) of wt KRAS DNA. Replicates were 273 
subjected to mutation-enrichment NGS analysis. The observed distribution of positive 274 
and negative hits in our experiments matched the theoretical hit rate of an ideal Poisson 275 
distribution for these replicates, confirming 1 copy detection sensitivity of the KRASG12/G13 276 
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assay in the background of 18,181 wt GEq (0.006%; Fig. 1C) and 2 copies detection 277 
sensitivity in a background of 100,000 wt GEq (0.002%; Supplementary Table S1).  278 
The reproducibility of quantitative KRASG12/G13 mutations detection was analyzed 279 
using urine samples from patients with advanced cancers. Two to three cups (each 90-280 
120 mL) of urine were obtained at a single time point from 3 patients with tumor biopsy 281 
specimens positive for KRASG12/G13 mutations. Intra-patient reproducibility of the urine 282 
KRASG12/G13 testing, calculated as the coefficient variation percent (CV%) for repeat 283 
measurements, varied from 2.3% to 19.6%. The average inter-patient reproducibility 284 
(CV%) was 9.7% (Table 1). 285 
 286 
Concordance, Sensitivity and Specificity of KRASG12/13 Mutation Detection in Urine 287 
cfDNA Compared to Tumor 288 
This blinded study with prospectively collected liquid biopsy samples enrolled 71 289 
patients with diverse advanced cancers and archival formalin-fixed paraffin-embedded 290 
(FFPE) tumor specimens with known KRASG12/G13 mutation status (Table 2). The 291 
patients’ median age was 59 years (range, 36–85 years). Most patients were white 292 
(n=51; 72%) and male (n=38; 54%). The most common tumor type was colorectal 293 
cancer (n=56; 79%), followed by breast cancer (n=4; 6%) and NSCLC (n=3; 4%). The 294 
median time from tissue to urine sampling was 23.0 months (range, 0.7–91.3 months), 295 
and the median time from tissue to plasma sampling was 16.9 months (range, 0.9–80.2 296 
months). The median amount of cfDNA isolated per 1 mL of urine was 9.1 ng (range, 297 
0.2–2057.0 ng) and that isolated per 1 mL of plasma was 18 ng (range, 3.1–605.4 ng). 298 
 Of the 71 patients, 49 (69%) had archival tumor specimens with KRASG12/G13 299 
mutations, and 31 (44%) had detectable KRASG12/G13 mutations in urine cfDNA. There 300 
was overall concordance in KRASG12/G13 mutation status between urine cfDNA and tumor 301 
specimens in 52 cases (73%; kappa, 0.49; standard error [SE], 0.09; 95% confidence 302 
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interval [CI], 0.31–0.66). The urine cfDNA test had a sensitivity of 63% (95% CI, 0.47–303 
0.76), specificity of 96% (95% CI, 0.78–1.00), and positive predictive value (PPV) of 97% 304 
(95% CI, 0.83–1.00; Table 3; Supplementary Table S2).  305 
Although the recommended volume for urine specimen collection was 90–110 306 
mL, urine specimens with smaller volumes were also collected (median, 60 mL; range, 307 
20–150 mL). Therefore, we investigated whether the collected amount of urine affected 308 
the concordance, sensitivity, and specificity of the urine cfDNA test. Among the 43 309 
patients who had urine specimens of > 50 mL, there was overall concordance in 310 
KRASG12/G13 mutation status between urine cfDNA and tumor specimens in 33 cases 311 
(77%; kappa, 0.55; SE, 0.11; 95% CI, 0.34–0.77), and the urine cfDNA test had a 312 
sensitivity of 66% (95% CI, 0.46–0.82), specificity of 100% (95% CI, 0.77–1.00), and 313 
PPV of 100% (95% CI, 0.82–1.00; Table 3). Among the 19 patients who had urine 314 
specimens of 90–110 mL, there was overall concordance in KRASG12/G13 mutation status 315 
between cfDNA and tumor specimens in 17 cases (89%; kappa, 0.79; SE, 0.14; 95% CI, 316 
0.52–1.00), and the urine cfDNA test had a sensitivity of 80% (95% CI, 0.44–0.97), 317 
specificity of 100% (95% CI, 0.66–1.00), and PPV of 100% (95% CI, 0.63–1.00; Table 318 
3). 319 
Of the 71 patients, 33 (46%) had simultaneous collection of plasma cfDNA and 320 
urine cfDNA. Among these 33 patients, there was overall concordance in KRASG12/G13 321 
mutation status between plasma cfDNA and tumor specimens in 31 cases (94%; kappa, 322 
0.86; SE, 0.10; 95% CI, 0.67–1.00). The plasma cfDNA test had a sensitivity of 92% 323 
(95% CI, 0.73–0.99), specificity of 100% (95% CI, 0.66–1.00), and PPV of 100% (95% 324 
CI, 0.85–1.00; Table 4; Supplementary Table S2). In addition, there was overall 325 
concordance in KRASG12/G13 mutation status between urine cfDNA and plasma cfDNA 326 
specimens in 22 cases (67%; kappa, 0.35; SE, 0.15; 95% CI, 0.07–0.64). Using plasma 327 
as the reference, the urine cfDNA test (10–110 mL) had a sensitivity of 59% (95% CI, 328 
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0.36–0.79), specificity of 82% (95% CI, 0.48–0.98), and PPV of 87% (95% CI, 0.60–329 
0.98; Table 4; Supplementary Table S2). 330 
 331 
KRASG12/G13-Mutant Copy Number and cfDNA Concentration and Survival 332 
To determine whether the number of KRASG12/G13-mutant copies in urine cfDNA 333 
was associated with OS, we first divided the 71 patients into 2 groups: those with < 26.3 334 
KRASG12/G13-mutant copies and those with ≥ 26.3 KRASG12/G13-mutant copies. The 335 
threshold was selected based on a 5% trimmed mean value of KRASG12/G13-mutant 336 
cfDNA. This was deemed to be appropriate as the median percentage of KRASG12/G13-337 
mutant cfDNA was 0% because 40 of the 71 patients had no KRASG12/G13 mutations in 338 
urine cfDNA. The median OS duration of the 57 patients with < 26.3 KRASG12/G13-mutant 339 
copies (11.1 months; 95% CI, 7.5–14.7 months) and that of the 14 patients with ≥ 26.3 of 340 
KRASG12/G13-mutant copies (16.5 months; 95% CI, 5.3–27.7 months) did not differ 341 
significantly (P = 0.63; Supplementary Fig. S3A). Similarly, again using a threshold 342 
selected based on a 5% trimmed mean, we found that the median OS duration of the 23 343 
patients with < 198.8 KRASG12/G13-mutant copies in plasma cfDNA (18.7 months; 95% 344 
CI, 3.5–33.9 months) and that of the 10 patients with ≥ 198.8 KRASG12/G13-mutant copies 345 
in plasma cfDNA (12.6 months; 95% CI, 11.6–13.4 months) did not differ significantly (P 346 
= 0.90; Supplementary Fig. S3B). 347 
 We next analyzed whether cfDNA concentrations in urine or plasma were 348 
associated with OS using thresholds selected based on median values. For the 69 of 71 349 
patients for whom urine cfDNA data were available, the median OS duration of the 35 350 
patients with < 9.1 ng of cfDNA/mL (13.0 months; 95% CI, 7.2–18.8 months) and that of 351 
the 34 patients with ≥ 9.1 ng of cfDNA/mL (11.1 months; 95% CI, 7.4–14.8 months) did 352 
not differ significantly (P = 0.31; Supplementary Fig. S4A). Similarly, for the 33 patients 353 
for whom plasma cfDNA data were available, the median OS duration of the 16 patients 354 
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with < 18.0 ng of cfDNA/mL (12.6 months; 95% CI, 5.9–19.2 months) and that of the 17 355 
patients with ≥ 18 ng of cfDNA/mL (20.6 months; 95% CI, 5.9–35.3 months) did not differ 356 
significantly (P = 0.19; Supplementary Fig. S4B). 357 
 358 
Serial Monitoring for KRASG12/13 Mutations in the cfDNA of Cancer Patients on 359 
Therapy 360 
At least 2 (median, 6; range, 2–13) longitudinal serial urine collections were 361 
obtained before and during patients’ systemic therapy, which ranged from first-line 362 
therapies to experimental therapies after all standard treatment had failed, from 21 363 
patients with KRASG12/G13 mutations in tumor tissue. Of these 21 patients, 17 (81%) had 364 
detectable KRASG12/G13 mutations in cfDNA in ≥ 1 urine specimen. The median 365 
KRASG12/G13 copy numbers in specimens collected at baseline (8.6), during therapy (0), 366 
and at disease progression (6.9) differed significantly (P = 0.002; Fig. 2A). The patients 367 
received 21 diverse systemic therapies (Supplementary Table S3). The best response to 368 
therapy (complete response [CR] or partial response [PR] or stable disease [SD] ≥ 6 369 
months vs. SD < 6 months or progressive disease [PD]) on imaging per Response 370 
Evaluation Criteria in Solid Tumors (RECIST) was not associated with the best change 371 
in KRASG12/G13 copy numbers (median change percentage, –100% for patients with 372 
CR/PR/SD ≥ 6 months vs. –100% for patients with SD < 6 months/PD; P = 0.24) (23). Of 373 
the 21 therapies, 16 decreased the KRASG12/G13 copy numbers, and 5 caused no change 374 
or increased the KRASG12/G13 copy numbers. The median TTF of the patients with a 375 
decrease in KRASG12/G13 copy numbers (4.7 months; 95% CI, 2.6–6.8 months) was 376 
significantly longer than that of the patients with no change or an increase in copy 377 
numbers (2.8 months; 95% CI, 2.6–3.0 months; P = 0.03; Fig. 3A).  378 
At least 2 (median, 5.5; range, 3–14) serial plasma collections were obtained 379 
before and during systemic therapy from 18 patients with KRASG12/G13 mutations in tumor 380 
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tissue. All 18 patients had detectable KRASG12/G13 mutations in cfDNA in ≥ 1 plasma 381 
specimen. The median KRASG12/G13 copy numbers at baseline (488.5), during therapy 382 
(11.0), and at disease progression (258.6) differed significantly (P < 0.001; Fig. 2B). The 383 
patients received 20 diverse systemic therapies (Supplementary Table S3). The best 384 
response to therapy (CR, PR, or SD ≥ 6 months vs. SD < 6 months or PD) on imaging 385 
per RECIST showed a trend towards association with the best change in copy numbers 386 
(median change percentage, –100% for CR/PR/SD ≥ 6 months vs. –36% in SD < 6 387 
months/PD; P = 0.09). Of the 18 therapies (2 therapies were excluded because of 388 
missing pre-treatment KRASG12/G13 copy number values), 12 decreased the KRASG12/G13 389 
copy numbers, and 6 caused no change or increased KRASG12/G13 copy numbers. The 390 
median TTF of the patients with a decrease in KRASG12/G13 copy numbers (5.7 months; 391 
95% CI, 2.8–8.6 months) was significantly longer than that of patients with no change or 392 
an increase in copy numbers (3.2 months; 95% CI, 2.1–4.3 months; P = 0.04; Fig. 3B). 393 
 394 
 395 
 396 
 397 
 398 
 399 
 400 
 401 
 402 
 403 
 404 
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DISCUSSION 405 
Our findings demonstrate that mutation enrichment leads to an approximately 406 
3,000-fold increase of the KRASG12/G13-mutant signal over the wt signal, which allows the 407 
detection of low-frequency mutant copies in samples of urine cfDNA. In a blinded study 408 
with prospectively collected samples, our assay using mutation-enrichment PCR coupled 409 
with NGS detected KRASG12/G13-mutant copies in urine cfDNA from patients with 410 
advanced cancers and had acceptable concordance (73–89%), sensitivity (63–80%), 411 
and specificity (96–100%) compared with the clinical testing of FFPE tumor tissue 412 
obtained at different times during routine care. The concordance increased with the 413 
amount of urine collected, which is ideally 90–110 mL. Furthermore, in a subset of 414 
patients for whom plasma cfDNA was available, we demonstrated excellent 415 
concordance of 94% with FFPE tumor tissue (sensitivity, 92%; specificity, 100%).  416 
Although preliminary data on the molecular testing of urine cfDNA have been 417 
published, to our knowledge, ours is the first report of the development and laboratory 418 
and clinical validation of a urine cfDNA assay, whose concordance with testing of clinical 419 
samples appears to be similar to previously published data on plasma cfDNA (10, 21). 420 
One recent study demonstrated in a similar patient population that the testing of plasma 421 
cfDNA for KRASG12/G13 mutations with BEAMing PCR is concordant with the standard-of-422 
care mutation analysis of FFPE primary or metastatic tumor in 83% of patients (24). A 423 
certain level of discordance can be anticipated if the tumor tissue and plasma are 424 
obtained at different times. Higgins et al. (25) found 100% concordance between testing 425 
plasma cfDNA with BEAMing PCR and testing simultaneously collected tumor tissue 426 
with conventional methods for PIK3CA mutations in a cohort of patients with advanced 427 
breast cancer. However, the concordance between the methods decreased to 79% in a 428 
cohort of patients whose tumor and plasma cfDNA samples were obtained at different 429 
times, which is consistent with our results. In another study of 100 patients with 430 
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advanced colorectal cancer, droplet digital PCR detection of RAS mutations in plasma 431 
cfDNA was in concordance with  archival tissue in 97% of cases (20). This rate was 432 
favorable compared with most other studies; however, the median time from tissue to 433 
plasma collection was only 43 days, which could explain the high concordance rate. In a 434 
phase III randomized trial of regorafenib vs. placebo, Tabernero et al. (26), using 435 
BEAMing PCR, showed concordant KRAS mutation status between plasma-derived 436 
cfDNA and archival tumor samples in 76% of tested patients with advanced colorectal 437 
cancer. Thierry et al. (27), using allele-specific quantitative PCR of plasma cfDNA and 438 
mutation detection in primary or metastatic tissue, demonstrated a 96% concordance for 439 
combined KRAS and BRAF mutation testing. Finally, Sacher et al. (28), in the only 440 
prospective study to date, demonstrated that digital droplet PCR detected KRASG12 441 
mutations in the plasma cfDNA in 64% of patients with known KRASG12 mutations in the 442 
tumor. Compared with most of these previous studies’ findings, our concordance results 443 
for KRASG12/G13 mutations in urine cfDNA were similar, and those for KRASG12/G13 444 
mutations in plasma cfDNA were favorable, despite the fact that the median times 445 
between archival tumor tissue collection and urine or plasma collection were relatively 446 
long (23.0 months and 16.9 months, respectively) and that fact that urine cfDNA is a far 447 
more challenging material because of its short fragments and low mutation allele 448 
frequencies (25-29). There is increasing evidence that the mutation analysis results for 449 
cfDNA are highly concordant with those for archival tumor tissue for concordantly, but 450 
not discordantly, collected samples, which may be explained by tumor biology, including 451 
tumor heterogeneity and evolution, and preanalytical factors such as inadequate 452 
specimen collection (28, 30). In addition, testing of urine cfDNA offers a completely non-453 
invasive method and urine collection does not need to be done by a trained personnel, 454 
which can expand the use of molecular cfDNA testing.    455 
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 In our study, we did not find any relationship between OS and KRASG12/G13 copy 456 
number values in urine or plasma cfDNA. An earlier study using BEAMing PCR to 457 
assess plasma cfDNA for KRASG12/G13 mutations in patients with advanced cancers 458 
found that a high amount of KRAS-mutant cfDNA was associated with shorter OS 459 
duration (4.8 months vs. 7.3 months; P = 0.008) (24). Another study that used the Idylla 460 
system to detect BRAFV600 mutations in plasma-derived cfDNA from patients with diverse 461 
advanced cancers showed that a higher percentage of BRAFV600-mutant cfDNA was 462 
associated with shorter OS (4.4 months vs. 10.7 months, P = 0.005) (31). Similarly, the 463 
phase III randomized trial of regorafenib vs. placebo showed that high baseline levels of 464 
KRAS-mutant cfDNA were associated with shorter OS durations in patients with 465 
advanced colorectal cancer (26). In other studies, higher amounts of KRAS-mutant 466 
cfDNA were associated with shorter OS durations in patients with advanced colorectal 467 
cancer treated with irinotecan and cetuximab and in patients with advanced NSCLC 468 
treated with carboplatin and vinorelbine (32, 33). Similarly, in a combined analysis of 469 
clinical trials of BRAF and MEK inhibitors in patients with advanced melanomas, a 470 
BRAFV600E mutation in cfDNA was associated with shorter OS duration (34). In contrast, 471 
in a study of patients with advanced NSCLC, those with EGFR exon 19 deletion in both 472 
the tissue and cfDNA had better survival than patients with EGFR exon 19 deletion in 473 
the tissue only (35). The results of our study may have been affected by the 474 
heterogeneity in the tumor types, setting of treatment administration (from first-line to 475 
third-line and higher, including clinical trials), and participating institutions and/or by its 476 
small sample sizes and large proportion of samples with less-than-optimal urine 477 
volumes; these factors may also explain some of the differences between our findings 478 
and those of previous studies. A larger prospective study to validate the clinical utility of 479 
KRAS mutation detection in the urine of patients with advanced colorectal cancer and it 480 
is association with treatment outcomes is ongoing. 481 
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 Previous studies have investigated the use of detecting molecular aberrations in 482 
cfDNA to monitor response to cancer therapy (19, 21, 36-44). In the present study, we 483 
assessed serially collected urine and plasma cfDNA from patients treated with systemic 484 
therapies and found that the KRASG12/G13 copy numbers before therapy, during therapy, 485 
and at the time of disease progression differed significantly. We also found that patients 486 
with a decrease in KRASG12/G13 copy numbers in serially collected urine or plasma cfDNA 487 
during therapy had a longer median TTF compared with patients with no change or an 488 
increase in copy numbers (4.7 vs. 2.8 months, P = 0.03 for urine; 5.7 vs. 3.2 months, P = 489 
0.04 for plasma). This observation is consistent with previously published data 490 
demonstrating that changes in plasma cfDNA can correspond with treatment outcomes 491 
(28, 29, 37-44). In particular, a study using the Idylla system to detect BRAFV600 492 
mutations in plasma-derived cfDNA from patients with colorectal or other advanced 493 
cancers found that the median TTF of patients who received therapies associated with a 494 
decrease in BRAF-mutant cfDNA (10.3 months) was significantly longer than that of 495 
patients who received therapies associated with an increase or no change in BRAF-496 
mutant cfDNA (7.4 months, P = 0.045) ((31).  Overall, however, there is conflicting 497 
evidence that such changes in cfDNA can predict or at least correspond with treatment 498 
outcomes, and this issue will need to be investigated in future prospective studies.  499 
Our study had several potential limitations. First, the amount of collected urine 500 
was suboptimal in many cases, which likely negatively impacted concordance and could 501 
have impacted serial monitoring analysis. Second, our study did not investigate if the 502 
timing of urine collection can impact results. Third, the sample size was limited. Fourth, 503 
we investigated only KRASG12/G13 mutations, which are clinically relevant to only a limited 504 
number of patients with certain tumor types. Finally, because of the heterogeneity in 505 
tumor types, systemic therapies and exploratory nature of the longitudinal analysis, the 506 
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association between changes in mutant cfDNA and TTF needs to be validated in future 507 
prospective studies. 508 
In summary, our study demonstrates that using mutation-enrichment PCR 509 
coupled with NGS to molecularly analyze urine cfDNA for the 7 most frequent hotspot 510 
KRASG12/G13 mutations is feasible and has good concordance with standard mutation 511 
testing of discordantly collected FFPE tumor tissue. Our results also suggest that the 512 
dynamics of KRASG12/G13-mutant copies in cfDNA corresponds with TTF. The clinical 513 
utility of cfDNA mutation testing is gaining increasing acceptance. Regulatory agencies 514 
in the United States and European Union have recently approved the use of an EGFR 515 
mutation plasma cfDNA test for advanced NSCLC when tissue is not available. The 516 
clinical utility of serial cfDNA testing is promising and should be further proven in future 517 
prospective clinical trials in which therapeutic interventions are tailored based on 518 
patients’ respective cfDNA mutation statuses. 519 
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Table 1. Reproducibility of the detection of KRASG12/G13 mutations in urine cell-free DNA 684 
from patients with advanced cancer. Two to three urine cups (each 90-120 mL) were 685 
collected at a single time point from 3 patients with known KRAS mutational status in 686 
tumor biopsies. Following urine extraction, cfDNA was assayed by mutation-enrichment 687 
NGS. Intra- and inter-patient reproducibility was calculated as CV%. 688 
Patient, Replicate 
KRAS 
Variant 
KRASG12/G13 
Copies 
CV% 
Average 
CV% 
1, 1 
G12S 
18.29 
2.3 
9.7 
1, 2 17.81 
1, 3 18.66 
2, 1 
G13D 
195.02 
7.0 
2, 2 176.57 
3, 1 
G12D 
10.43 
19.6 3, 2 7.26 
3, 3 7.91 
Abbreviation: CV%, coefficient variation percent. 689 
 690 
 691 
 692 
  693 
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Table 2. Characteristics of 71 patients enrolled in the study. 694 
Characteristic No. of Patients (%)* 
Median age (range), years 59 (36-85) 
Gender  
Male 38 (54) 
Female 33 (46) 
Ethnicity  
Caucasian 51 (72) 
Hispanic 12 (17) 
African American 5 (7) 
Asian 3 (4) 
Cancer type  
Colorectal cancer 56 (79) 
Breast cancer 4 (6) 
Non-small cell lung cancer 3 (4) 
Pancreatic cancer 2 (<3) 
Ovarian cancer 2 (<3) 
Other cancers 4 (6) 
KRAS status in the tissue  
G12C 7 (10) 
G12D 24 (34) 
G12R 2 (3) 
G12S 6 (8) 
G12V 6 (8) 
G13D 3 (4) 
Wild-type 23 (32) 
KRAS status in urine cfDNA  
G12C 4 (6) 
G12D 17 (24) 
G12R 1 (<1) 
G12S 4 (6) 
G12V 3 (4) 
G13D 2 (<3) 
Wild-type 40 (56) 
KRAS status in plasma cfDNA (N=33)  
G12C 2 (6) 
G12D 12 (36) 
G12S 2 (6) 
G12V 3 (9) 
G13D 3 (9) 
Wild-type 11 (33) 
*Unless otherwise indicated. 695 
 696 
  697 
30 
 
Table 3. Concordance assessment of KRASG12/G13 mutations in formalin-fixed, paraffin-698 
embedded (FFPE) tumor tissue and urine cell-free DNA (cfDNA) from patients with 699 
advanced cancers. 700 
Concordance for urine samples collected before systemic therapy tested for KRASG12/G13 mutations versus 
FFPE tumor samples tested in the clinical laboratory 
Number of patients, N=71 KRAS
G12/G13 Mutation in 
Tumor 
KRASG12/G13 Wild-Type in 
Tumor 
KRASG12/G13 mutation in cfDNA, no. of 
patients  30 1 
KRASG12/G13 wild-type in cfDNA, no. of 
patients  18 22 
Observed concordance   52 (73%); kappa, 0.49; SE, 0.09; 95% CI, 0.31-0.66 
Sensitivity 63% (95% CI, 0.47-0.76) 
Specificity 96% (95% CI, 0.78-1.00) 
Positive predictive value 97% (95% CI, 0.83-1.00) 
 
Concordance for urine samples (> 50 mL of urine) collected before systemic therapy tested for KRASG12/G13 
mutations versus FFPE tumor samples tested in the clinical laboratory 
Number of patients, N=43 KRAS
G12/G13 Mutation in 
Tumor 
KRASG12/G13 Wild-Type in 
Tumor 
KRASG12/G13 mutation in cfDNA, no. of 
patients 19 0 
KRASG12/G13 wild-type in cfDNA, no. of 
patients 10 14 
Observed concordance  33 (77%); kappa, 0.55; SE, 0.11; 95% CI, 0.34-0.77 
Sensitivity 66% (95% CI, 0.46-0.82) 
Specificity 100% (95% CI, 0.77-1.00) 
Positive predictive value 100% (95% CI, 0.82-1.00) 
 
Concordance for urine samples (90-110 mL of urine) collected before systemic therapy tested for 
KRASG12/G13 mutations versus FFPE tumor samples tested in the clinical laboratory 
Number of patients, N=19 KRAS
G12/G13 Mutation in 
Tumor 
KRASG12/G13 Wild-Type in 
Tumor 
KRASG12/G13 mutation in cfDNA, no. of 
patients 8 0 
KRASG12/G13 wild-type in cfDNA, no. of 
patients  2 9 
Observed concordance  17 (89%); kappa, 0.79; SE, 0.14; 95% CI, 0.52-1.00 
Sensitivity 80% (95% CI, 0.44-0.97) 
Specificity 100% (95% CI, 0.66-1.00) 
Positive predictive value 100% (95% CI, 0.63-1.00) 
 701 
 702 
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Table 4. Concordance assessment of KRASG12/G13 mutations in plasma cell-free DNA 703 
(cfDNA) and formalin-fixed, paraffin-embedded (FFPE) tumor tissue or urine cfDNA from 704 
patients with advanced cancers. 705 
Concordance for plasma samples collected before systemic therapy tested for KRASG12/G13 mutations 
versus FFPE tumor samples tested in the clinical laboratory 
Number of patients, N=33 KRAS
G12/G13 Mutation in 
Tumor 
KRASG12/G13 Wild-Type in 
Tumor 
KRASG12/G13 mutation in plasma, no. of 
patients  22 0 
KRASG12/G13 wild-type in plasma, no. of 
patients  2 9 
Observed concordance  31 (94%); kappa, 0.86; SE, 0.10; 95% CI, 0.67-1.00 
Sensitivity 92% (95% CI, 0.73-0.99) 
Specificity 100% (95% CI, 0.66-1.00) 
Positive predictive value 100% (95% CI, 0.85-1.00) 
 
Concordance for plasma and urine samples collected before systemic therapy tested for KRASG12/G13 
mutations  
Number of patients, N=33 KRAS
G12/G13 mutation in 
plasma KRAS
G12/G13 wild-type in plasma 
KRASG12/G13 mutation in urine, no. of 
patients 13 2 
KRASG12/G13 wild-type in urine, no. of 
patients 9 9 
Observed concordance  22 (67%); kappa, 0.35; SE, 0.15; 95% CI, 0.07-0.64 
Sensitivity 59% (95% CI, 0.36-0.79) 
Specificity 82% (95% CI, 0.48-0.98) 
Positive predictive value 87% (95% CI, 0.60-0.98) 
 706 
 707 
  708 
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Figure Legends 709 
Figure 1. Mutation-enrichment next-generation sequencing (NGS) platform for the 710 
analysis of cell-free DNA from urine and plasma. A. Comparison between the input ratio 711 
of mutant/wild-type (wt) KRASG12/G13 copies and the output ratio of mutant/wt 712 
KRASG12/G13 sequencing reads for 5-500 input mutant copies of the 7 most common 713 
KRASG12/G13 variants diluted in 60 ng (~18,180 genome equivalents) of wt DNA (mutation 714 
abundance, 0.0275-2.75%).  The output sequencing reads are the means of 18 715 
replicates from 6 independent NGS dilution series experiments performed on 3 different 716 
days by 2 operators on 2 MiSeq instruments. B. Fold enrichment was calculated as the 717 
percent of input mutant KRASG12/G13 molecules divided by the percent of output mutant 718 
KRASG12/G13 sequencing reads in A. C. Verification of the analytical sensitivity (lower limit 719 
of detection, 1) of the KRASG12/G13 mutation-enrichment NGS assay. A DNA blend with 720 
20 mutant copies in a background of ~363,620 wt genome equivalents (0.006%) was 721 
prepared and distributed over 20 wells to achieve a target concentration of 1 mutant 722 
copy/18,181 genome equivalents per well. Following mutation-enrichment NGS, the 723 
observed distribution frequency of the counts of 0 or ≥1 copies across 20 replicates was 724 
compared to theoretical Poisson expectations (95% confidence intervals [CIs]). 725 
 726 
Figure 2. A. The median KRASG12/G13 copy numbers in urine at baseline (8.6), on 727 
therapy (0), and at disease progression (6.9) differed significantly (P = 0.002). B. The 728 
median KRASG12/G13 copy numbers in plasma at baseline (488.5), during therapy (11.0), 729 
and at disease progression (258.6) also differed significantly (P < 0.001). 730 
 731 
Figure 3. Association between changes in cell-free DNA KRASG12/13 copies and time to 732 
treatment failure (TTF). A. The median TTF of patients with a decrease in KRASG12/G13 733 
copy numbers in urine (4.7 months; 95% CI, 2.6-6.8 months; blue) was significantly 734 
33 
 
longer than that of patients with no change or an increase in KRASG12/G13 copy numbers 735 
in urine (2.8 months; 95% CI, 2.6-3.0 months; red; P = 0.03). B. The median TTF of 736 
patients with a decrease in KRASG12/G13 copy numbers in plasma (5.7 months; 95% CI, 737 
2.8-8.6 months; blue) was significantly longer than that of patients with no change or an 738 
increase in KRASG12/G13 copy numbers in plasma (3.2 months; 95% CI, 2.1-4.3 months; 739 
red; P = 0.04). 740 
 741 
Number of Mutant Copies 0 (Not Detected) 1+ (Detected) 
   Expected (95% CI)  
   [1 copy/replicate]* 7 (2-14) 13 (6-20) 
   Observed:  
G12A 
 
12 
 
8 
G12C 5 15 
G12D 3 17 
G12R 10 10 
G12S 6 14 
G12V 4 16 
G13D 3 17 
A 
B C 
Figure 1.  
 Input MT Copies/WT 
Copies (% Mutant) 
Output Mutant Sequencing Reads/Wild Type Reads (% Mutant Reads) 
KRAS G12A KRAS G12C KRAS G12D KRAS G12R KRAS G12S KRAS G12V KRAS G13D 
5/18,181 (0.027%) 
4151/1381 
(62%) 
6661/2928 
(72%) 
13447/858 
(91%) 
4100/1570  
(54%) 
2440/882  
(67%) 
4269/410  
(90%) 
2318/748  
(79%) 
15/18,181 (0.082%) 
14365/1133 
(92%) 
2586/864  
(74%) 
34363/1155 
(96%) 
37445/2050 
(95%) 
4614/1774 
(73%) 
9068/423  
(95%) 
15726/1053 
(92%) 
125/18,181 (0.68%) 
133074/2662 
(98%) 
72469/1392 
(97%) 
156863/1855 
(99%) 
195110/3634 
(98%) 
15486/1572 
(88%) 
144666/1821 (99%) 
170503/1348 
(99%) 
250/18,181 (1.36%) 
161048/3353 
(98%) 
112052/1406 
(99%) 
309123/2307 
(99%) 
281142/5513 
(98%) 
27344/760 
(97%) 
267933/2452 (99%) 
331498/2216 
(99%) 
500/18,181 (2.7%) 
229638/3190 
(99%) 
194430/3085 
(98%) 
508045/1442 
(100%) 
372965/3168 
(99%) 
41137/632 
(98%) 
472491/2836 (99%) 
585254/1807 
(100%) 
Figure 2.  
A.  B.  Plasma Urine 
Figure 3.  
A.  B.  Plasma 
cfDNA KRASG12/13 decrease 
cfDNA KRASG12/13 increase or no change 
Urine 
cfDNA KRASG12/13 decrease 
cfDNA KRASG12/13 increase or no change 
